S. MacLachlan

First name
S.
Last name
MacLachlan
Harris, L., Graham, S., MacLachlan, S., Exuzides, A., & Jacob, S. (2022). A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis. Bmc Neurol, 22, 172. http://doi.org/10.1186/s12883-022-02692-4
Merinopoulou, E., Raluy-Callado, M., Ramagopalan, S., MacLachlan, S., & Khalid, J. M. (2016). COPD exacerbations by disease severity in England. Int J Chron Obstruct Pulmon Dis. http://doi.org/10.2147/copd.s100250
van Brunt, K., Curtis, B., Ivanyi, T., Balogh, E., Chalkiadaki, C., MacLachlan, S., et al. (2016). Basal-bolus Therapy in Patients with Type 2 Diabetes Mellitus in the UK: Patient Characteristics, Treatment Patterns and the Effect of Switching to Premixed Insulin. Diabetes Ther. http://doi.org/10.1007/s13300-016-0209-4
Disanto, G., Zecca, C., MacLachlan, S., Sacco, R., Handunnetthi, L., Meier, U. C., et al. (2018). Prodromal symptoms of multiple sclerosis in primary care. Ann Neurol. http://doi.org/10.1002/ana.25247
Horne, L., Ashfaq, A., MacLachlan, S., Sinsakul, M., Qin, L., LoCasale, R., & Wetmore, J. B. (2019). Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England. BMC Nephrol. http://doi.org/10.1186/s12882-019-1250-0
Harris, L., Graham, S., MacLachlan, S., Exuzides, A., & Jacob, S. (2019). Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England. J Med Econ. http://doi.org/10.1080/13696998.2019.1592180
Cherney, D. Z. I., Repetto, E., Wheeler, D. C., Arnold, S. V., MacLachlan, S., Hunt, P. R., et al. (2019). Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus. Am J Nephrol. http://doi.org/10.1159/000504558
Zecca, C., Disanto, G., Sacco, R., MacLachlan, S., Kuhle, J., Ramagopalan, S. V., & Gobbi, C. (2020). Increasing cancer risk over calendar year in people with multiple sclerosis: a case-control study. J Neurol. http://doi.org/10.1007/s00415-020-10170-5